Author

X. Y. Woo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Research Focus:cell type annotation· 2 Research Focus:clustering· 2 Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:variant calling· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

A. L. Welm· 2 shared A. Srivastava· 2 shared C.-H. Yang· 2 shared E. Cortes-Sanchez· 2 shared M. W. Lloyd· 2 shared A. Bertotti· 1 shared A. C. Beck· 1 shared A. C. O'Farrell· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. L. Welm

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A Genomically and Clinically Annotated Patient Derived Xenograft (PDX) Resource for Preclinical Research in Non-Small Cell Lung Cancer

X. Y. Woo, A. Srivastava, P. C. Mack, J. H. Graber, B. J. Sanderson, M. W. Lloyd, M. Chen, S. Domanskyi, R. Gandour-Edwards, R. A. Tsai, J. Keck, M. Cheng, M. Bundy, E. L. Jocoy, J. W. Riess, , C. J. Bult

The paper describes a collection of 79 genomically and clinically annotated lung cancer PDX models that retain patient tumor features and treatment responses, available through MMHCdb.

bioRxiv · Mar 6, 2022Cancer Biology

A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncology

K. P. Guillen, M. Fujita, A. J. Butterfield, S. D. Scherer, M. H. Bailey, Z. Chu, Y. S. DeRose, L. Zhao, E. Cortes-Sanchez, C.-H. Yang, J. Toner, G. Wang, Y. Qiao, X. Huang, J. A. Greenland, , A. L. Welm

The paper develops patient-derived xenografts and organoids for breast cancer to enable drug screening and precision oncology, showing efficacy of an FDA-approved drug in a clinical case.

bioRxiv · Feb 28, 2021 · PreprintCancer Biology

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

X. Y. Woo, J. Giordano, A. Srivastava, Z.-M. Zhao, M. W. Lloyd, R. de Bruijn, Y.-S. Suh, R. Patidar, L. Chen, S. Scherer, M. Bailey, C.-H. Yang, E. Cortes-Sanchez, Y. Xi, J. Wang, , B. E Welm

This study shows that copy number profiles are conserved in patient-derived xenografts (PDXs) through engraftment and passaging, indicating minimal impact from the mouse host on tumor evolution.

bioRxiv · Dec 3, 2019Cancer Biology